{"id":56888,"date":"2026-02-11T21:38:24","date_gmt":"2026-02-11T13:38:24","guid":{"rendered":"https:\/\/flcube.com\/?p=56888"},"modified":"2026-02-11T21:38:26","modified_gmt":"2026-02-11T13:38:26","slug":"astrazeneca-reports-8-revenue-growth-to-58-7-billion-in-2025-oncology-leads-with-17-surge","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56888","title":{"rendered":"AstraZeneca Reports 8% Revenue Growth to $58.7 Billion in 2025; Oncology Leads with 17% Surge"},"content":{"rendered":"\n

AstraZeneca PLC<\/strong> (AZ, NASDAQ:\u202fAZN<\/a><\/strong>) delivered strong 2025 financial results<\/strong>, with total revenues rising 8% year-on-year in constant currency to USD\u202f58.739 billion<\/strong>, driven by double-digit growth in Oncology and Respiratory & Immunology<\/strong>. The UK-based pharmaceutical giant<\/strong> issued 2026 guidance for mid-to-high single-digit percentage revenue growth<\/strong>, while discontinuing enrollment<\/strong> in a Phase III Datroway combination trial<\/strong> in early-stage NSCLC<\/strong>.<\/p>\n\n\n\n

Financial Performance Summary<\/h2>\n\n\n\n
Metric<\/th>2025 Result<\/th>YoY Change (CC)<\/th>Key Driver<\/th><\/tr><\/thead>
Total Revenues<\/strong><\/td>USD\u202f58.739 billion<\/td>+8%<\/strong><\/td>Oncology (+17%), R&I (+12%) strength<\/td><\/tr>
Q4 Revenues<\/strong><\/td>USD\u202f15.503 billion<\/td>+2%<\/strong><\/td>Quarterly deceleration vs. full-year momentum<\/td><\/tr>
2026 Guidance<\/strong><\/td>Mid-to-high single-digit growth<\/td>\u2013<\/td>Continued portfolio expansion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Business Segment Performance<\/h2>\n\n\n\n

Oncology: Primary Growth Engine (+17% to USD\u202f25.6B)<\/h3>\n\n\n\n
Product<\/th>2025 Sales<\/th>YoY Growth<\/th>Strategic Position<\/th><\/tr><\/thead>
Tagrisso (osimertinib)<\/strong><\/td>USD\u202f7.254 billion<\/td>+10%<\/strong><\/td>EGFR-mutated NSCLC global standard; adjuvant expansion<\/td><\/tr>
Imfinzi (durvalumab)<\/strong><\/td>USD\u202f6.063 billion<\/td>+28%<\/strong><\/td>PD-L1 leader in Stage III NSCLC; SCLC and biliary tract growth<\/td><\/tr>
Enhertu (T-DXd)<\/strong><\/td>USD\u202f4.982 billion<\/td>+32.7%<\/strong><\/td>HER2 ADC blockbuster; expanding into HER2-low and gastric cancer<\/td><\/tr>
Truqap (capivasertib)<\/strong><\/td>USD\u202f728 million<\/td>+68%<\/strong><\/td>AKT inhibitor in HR+\/HER2- breast cancer; rapid uptake<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Cardiovascular, Renal & Metabolism (+2% to USD\u202f12.8B)<\/h3>\n\n\n\n

| Farxiga (dapagliflozin)<\/strong> | USD\u202f8.405 billion | +9%<\/strong> | SGLT2 inhibitor across diabetes, heart failure, CKD |<\/p>\n\n\n\n

Respiratory & Immunology (+12% to USD\u202f8.9B)<\/h3>\n\n\n\n

| Symbicort Turbuhaler<\/strong> | USD\u202f2.885 billion | Stable | Asthma\/COPD maintenance; biosimilar competition mitigation |<\/p>\n\n\n\n

Rare Disease (+5% to USD\u202f9.1B)<\/h3>\n\n\n\n

| Ultomiris (ravulizumab)<\/strong> | USD\u202f4.718 billion | +19%<\/strong> | Long-acting C5 inhibitor; switching from Soliris complete |<\/p>\n\n\n\n

Vaccines & Immune Therapies (-3% to USD\u202f1.3B)<\/h3>\n\n\n\n

| Beyfortus (nirsevimab)<\/strong> | USD\u202f703 million | +26%<\/strong> | RSV monoclonal; infant protection; offset by COVID vaccine decline |<\/p>\n\n\n\n

Geographic Revenue Breakdown<\/h2>\n\n\n\n
Market<\/th>2025 Sales<\/th>YoY Growth (CC)<\/th>Strategic Insight<\/th><\/tr><\/thead>
United States<\/strong><\/td>USD\u202f25.45 billion<\/td>+10%<\/strong><\/td>Pricing power and novel therapy adoption<\/td><\/tr>
Emerging Markets<\/strong><\/td>USD\u202f15.303 billion<\/td>+14%<\/strong><\/td>Volume growth; access expansion<\/td><\/tr>
Emerging Markets (ex-China)<\/strong><\/td>USD\u202f8.649 billion<\/td>+22%<\/strong><\/td>Fastest-growing region<\/strong>; India, Brazil, Southeast Asia<\/td><\/tr>
Europe<\/strong><\/td>USD\u202f12.739 billion<\/td>+1%<\/strong><\/td>Austerity pricing pressure; biosimilar erosion<\/td><\/tr>
China<\/strong><\/td>USD\u202f6.654 billion<\/td>+4%<\/strong><\/td>NRDL pricing impact; volume offsetting price cuts<\/td><\/tr>
Other Markets<\/strong><\/td>USD\u202f5.247 billion<\/td>+6%<\/strong><\/td>Japan, Australia, Canada stability<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Development Update: Datroway Trial Discontinuation<\/h2>\n\n\n\n
Trial<\/th>Datroway (datopotamab deruxtecan) Phase III<\/th><\/tr><\/thead>
Design<\/strong><\/td>Datroway + rilvegostomig (bispecific) vs. rilvegostomig monotherapy<\/td><\/tr>
Population<\/strong><\/td>Stage I adenocarcinoma NSCLC; ctDNA-positive or high-risk post-resection<\/td><\/tr>
Status<\/strong><\/td>Patient enrollment discontinued<\/strong> (Feb\u202f2026)<\/td><\/tr>
Implication<\/strong><\/td>Strategic portfolio prioritization; resources reallocation to higher-probability oncology programs<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding AstraZeneca’s 2026 revenue growth trajectory, Datroway clinical development strategy, and regional market performance. Actual results may differ due to competitive dynamics in oncology (Enhertu vs. Trodelvy), pricing pressure in Europe and China, and pipeline execution risks.-Fineline Info & Tech<\/a><\/p>\n\n\n\n